SAFIR 03: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib (clinicaltrials.gov) - Oct 15, 2026 - P2 | N=4 | Terminated | Sponsor: UNICANCER | N=162 ➔ 4 | Trial completion date: Jun 2030 ➔ Jan 2026 | Active, not recruiting ➔ Terminated; poor accrual
Circulating tumor DNA • Enrollment change • Trial completion date • Trial termination • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER • HER-2 • PGR • PIK3CA
|